Keyphrases
Polycystic Kidney Disease
100%
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
100%
Angiotensin-converting Enzyme Inhibitor (ACEi)
100%
Trial Design
100%
Trial Implementation
100%
BP Control
100%
Egfr
75%
Monotherapy
50%
Hypertensive
50%
Kidney Disease Progression
50%
Angiotensin Receptor Blockers
50%
Renin-angiotensin-aldosterone System
50%
Kidney Volume
50%
Patient Outcomes
25%
Potential Gains
25%
Randomized Placebo-controlled Trial
25%
Patient Safety
25%
Quality of Life
25%
Kidney Outcomes
25%
Patient Quality
25%
Two-level
25%
Life Safety
25%
Composite Endpoint
25%
Four-arm
25%
Percent Change
25%
2-design
25%
Home BP
25%
Novel Endpoints
25%
Progressive Renal Disease
25%
RAAS Inhibition
25%
HALT PKD Trials
25%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Polycystic Disease
100%
Dipeptidyl Carboxypeptidase Inhibitor
80%
Kidney Disease
60%
Monotherapy
40%
Renin
40%
Angiotensin
40%
Disease Exacerbation
40%
Aldosterone
40%
Angiotensin Receptor Antagonist
40%
Placebo
20%
End Stage Renal Disease
20%
Medicine and Dentistry
Polycystic Kidney Disease
100%
ACE Inhibitor
80%
Nephropathy
60%
Monotherapy
40%
Renin Angiotensin Aldosterone System
40%
Angiotensin Receptor Antagonist
40%
Arm
20%
Placebo
20%
End Stage Renal Disease
20%
Quality of Life
20%
Biochemistry, Genetics and Molecular Biology
Angiotensin-Converting Enzyme
100%
Enzyme Inhibitor
100%
Autosomal Dominant Polycystic Kidney
100%
Renin Angiotensin Aldosterone System
50%
Angiotensin Receptor
50%